Safety and preliminary efficacy of 6-monthly subcutaneous CAP256V2LS plus VRC07-523LS for HIV prevention in African women: results of the CAPRISA 012C phase 2 randomised controlled trial w

Conference Reports for NATAP

13th IAS Conference on HIV Science
IAS 2026
July 26-31 Rio, Brazil


Safety and preliminary efficacy of 6-monthly subcutaneous CAP256V2LS plus VRC07-523LS for HIV prevention in African women: results of the CAPRISA 012C phase 2 randomised controlled trial

	S. MAHOMED IAS 2026 Rio Brazil